What Is Lexicon Pharmaceuticals, Inc. (LXRX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Lexicon Pharmaceuticals, Inc.'s intrinsic value is estimated at $0.65. Trading at its current price of $2.12, the valuation engine raises significant caution: 10 of 11 models flag downside risk, projecting an average implied return of -69.3%. Notably, PWERM sees the most upside at -5.0% (fair value: $2.01), while EPV is the most conservative at -90.4% ($0.20). The spread between these extremes — +85.4% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About LXRX?
11 of 13 models are currently active for LXRX. All 11 active models suggest the stock trades above fair value. The Bayesian DCF estimates LXRX's intrinsic value at $0.45, implying -78.9% downside from the current price. See which stocks rank higher →
How Does LXRX Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, LXRX ranks #53 by Quality of Company score. CirclFi's QOC score of 7.3/10 evaluates 32 fundamental signals. A score of 7.3 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to healthcare company businesses. For Lexicon Pharmaceuticals, Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.
Is LXRX a Value Trap?
CirclFi's Value Trap algorithm assigns LXRX a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for Lexicon Pharmaceuticals, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Lexicon Pharmaceuticals, Inc. scores 7.3 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +85.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every LXRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across LXRX's 11 active models, average confidence is 24%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad